Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 51Thoracic 11Other solid neoplasm 4Head & Neck 4Gynecologic 4Breast 4Tumor-Agnostic 2Lymphoid 2CNS 2Sarcoma 1

Conditions

Neoplasms, Unknown Primary 1Neoplasm Metastasis 1

Interventions

pembrolizumab 56Specimen Handling 28Biopsy 27Magnetic Resonance Spectroscopy 26Paclitaxel 22Blood Specimen Collection 21Nivolumab 20atezolizumab 18Standard of Care 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 17Oxaliplatin 13Fluorouracil 13Cisplatin 13Radiotherapy 12Radiosurgery 12Cyclophosphamide 12Pemetrexed 11Leucovorin 11Irinotecan 10Gemcitabine 10Docetaxel 10Capecitabine 10trastuzumab deruxtecan 8olaparib 8Taxes 8Ipilimumab 8durvalumab 7Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
sintilimab × Tumor-Agnostic × 1 year × Clear all
NCT07455617 2026-04-06

Study of ABO2102 in KRAS-Mutated Solid Tumors

Suzhou Abogen Biosciences Co., Ltd.

Phase 1 Recruiting
101 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05024968 2026-02-25

Sintilimab in Cancer of Unknown Primary

M.D. Anderson Cancer Center

Phase 2 Completed
10 enrolled 9 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡